| |
| |
| Exchange: |
Over The Counter |
| Security
Type: |
Common |
| Shares
Out: |
570,750,000 |
| Market
Cap: |
76.54(M) |
| Last
Volume: |
3,709,408 |
Avg
Vol: |
3,188,549 |
| 52
Week Range: |
$0.1356 - $0.3 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile CytoDyn is a clinical-stage biotechnology company focused on the clinical development of treatments for multiple therapeutic indications based on its product candidate, leronlimab, a humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor. Leronlimab is being investigated as a viral entry inhibitor for Human Immunodeficiency Virus. Leronlimab is also being studied in oncology, as well as other therapeutic indications, including coronavirus disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kelly Scott A. |
CMO |
• • – |
2022-04-15 |
4 |
A |
$0.00 |
$0 |
D/D |
21,367 |
1,972,022 |
|
- |
|
| Migliarese Antonio |
CFO & Interim President |
• – – |
2022-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
11,683 |
14,706 |
|
- |
|
| Recknor Chris P |
See Remarks |
• – – |
2022-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
12,950 |
699,000 |
|
- |
|
| Ray Nitya G. |
Chief Technology Officer |
• – – |
2022-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
14,780 |
302,081 |
|
- |
|
| Kelly Scott A. |
CMO |
• • – |
2022-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
15,592 |
1,950,655 |
|
- |
|
| Urbach Tanya Durkee |
Director |
– • – |
2021-11-24 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
162,113 |
|
-75% |
|
| Naydenov Jordan G |
Director |
– • – |
2021-09-23 |
4 |
OE |
$0.45 |
$700,000 |
D/D |
1,288,888 |
7,990,211 |
|
- |
|
| Kelly Scott A. |
Chairman & CMO |
• • – |
2021-08-06 |
4 |
A |
$0.00 |
$0 |
D/D |
194,011 |
1,935,063 |
|
- |
|
| Pourhassan Nader |
President & CEO |
• • – |
2021-08-06 |
4 |
A |
$0.00 |
$0 |
D/D |
275,758 |
1,850,688 |
|
- |
|
| Ray Nitya G. |
Chief Technology Officer |
• – – |
2021-08-06 |
4 |
A |
$0.00 |
$0 |
D/D |
87,301 |
287,301 |
|
- |
|
| Recknor Chris P |
Chief Operating Officer |
• – – |
2021-08-06 |
4 |
A |
$0.00 |
$0 |
D/D |
19,384 |
686,050 |
|
- |
|
| Migliarese Antonio |
Chief Financial Officer |
• – – |
2021-08-06 |
4 |
A |
$0.00 |
$0 |
D/D |
3,023 |
3,023 |
|
- |
|
| Gardiner Gordon A |
Director |
– • – |
2021-07-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,000 |
|
-33% |
|
| Naydenov Jordan G |
Director |
– • – |
2021-04-19 |
4 |
OE |
$1.35 |
$337,500 |
D/D |
250,000 |
6,701,323 |
|
- |
|
| Recknor Chris P |
Chief Operating OfficerOfficer |
• – – |
2021-03-11 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
666,666 |
|
-25% |
|
| Kelly Scott A. |
Chairman & CMO |
• • – |
2021-02-05 |
4 |
OE |
$0.75 |
$124,500 |
I/I |
166,000 |
782,408 |
|
- |
|
| Mulholland Michael D |
Chief Financial Officer |
• – – |
2020-12-22 |
4 |
AS |
$5.49 |
$4,437,557 |
D/D |
(711,801) |
284,081 |
|
-44% |
|
| Mulholland Michael D |
Chief Financial Officer |
• – – |
2020-12-22 |
4 |
OE |
$0.87 |
$742,767 |
D/D |
711,801 |
995,882 |
|
- |
|
| Mulholland Michael D |
Chief Financial Officer |
• – – |
2020-12-21 |
4/A |
AS |
$5.58 |
$3,269,919 |
D/D |
(585,797) |
284,081 |
|
- |
|
| Mulholland Michael D |
Chief Financial Officer |
• – – |
2020-12-21 |
4 |
AS |
$5.58 |
$3,292,247 |
D/D |
(589,797) |
284,081 |
|
-48% |
|
| Mulholland Michael D |
Chief Financial Officer |
• – – |
2020-12-21 |
4 |
OE |
$0.57 |
$431,644 |
D/D |
589,797 |
873,878 |
|
- |
|
| Mulholland Michael D |
Chief Financial Officer |
• – – |
2020-12-18 |
4 |
AS |
$4.95 |
$2,411,439 |
D/D |
(487,002) |
284,081 |
|
-37% |
|
| Mulholland Michael D |
Chief Financial Officer |
• – – |
2020-12-18 |
4 |
OE |
$0.39 |
$230,953 |
D/D |
487,002 |
771,083 |
|
- |
|
| Mulholland Michael D |
Chief Financial Officer |
• – – |
2020-12-17 |
4 |
AS |
$4.55 |
$145,674 |
D/D |
(32,000) |
284,081 |
|
-40% |
|
| Mulholland Michael D |
Chief Financial Officer |
• – – |
2020-12-17 |
4 |
OE |
$0.39 |
$12,480 |
D/D |
32,000 |
316,081 |
|
- |
|
381 Records found
|
|
Page 3 of 16 |
|
|
